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Abstract: Background Acute kidney injury (AKI) associated with severe coronavirus disease 19 (COVID-
19) is common and is a significant predictor of morbidity and mortality, especially when dialysis is
required. Case reports and autopsy series have revealed that most patients with COVID-19 – associated
acute kidney injury have evidence of acute tubular injury and necrosis - not unexpected in critically
ill patients. Others have been found to have collapsing glomerulopathy, thrombotic microangiopathy
and diverse underlying kidney diseases. A primary kidney pathology related to COVID-19 has not yet
emerged. Thus far direct infection of the kidney, or its impact on clinical disease remains controversial.
The management of AKI is currently supportive. Case Presentation The patient presented here was
positive for SARS-CoV-2, had severe acute respiratory distress syndrome and multi-organ failure. Within
days of admission to the intensive care unit he developed oliguric acute kidney failure requiring dialysis.
Acute kidney injury developed in the setting of hemodynamic instability, sepsis and a maculopapular
rash. Over the ensuing days the patient also developed transfusion-requiring severe hemolysis which
was Coombs negative. Schistocytes were present on the peripheral smear. Given the broad differential
diagnoses for acute kidney injury, a kidney biopsy was performed and revealed granulomatous tubulo-
interstitial nephritis with some acute tubular injury. Based on the biopsy findings, a decision was taken
to adjust medications and initiate corticosteroids for presumed medication-induced interstitial nephritis,
hemolysis and maculo-papular rash. The kidney function and hemolysis improved over the subsequent
days and the patient was discharged to a rehabilitation facility, no-longer required dialysis. Conclusions
Acute kidney injury in patients with severe COVID-19 may have multiple causes. We present the first case
of granulomatous interstitial nephritis in a patient with COVID-19. Drug-reactions may be more frequent
than currently recognized in COVID-19 and are potentially reversible. The kidney biopsy findings in this
case led to a change in therapy, which was associated with subsequent patient improvement. Kidney
biopsy may therefore have significant value in pulling together a clinical diagnosis, and may impact
outcome if a treatable cause is identified.
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Abstract
Background: Acute kidney injury (AKI) associated with severe coronavirus disease 19 (COVID-19) is common and is
a significant predictor of morbidity and mortality, especially when dialysis is required. Case reports and autopsy
series have revealed that most patients with COVID-19 – associated acute kidney injury have evidence of acute
tubular injury and necrosis - not unexpected in critically ill patients. Others have been found to have collapsing
glomerulopathy, thrombotic microangiopathy and diverse underlying kidney diseases. A primary kidney pathology
related to COVID-19 has not yet emerged. Thus far direct infection of the kidney, or its impact on clinical disease
remains controversial. The management of AKI is currently supportive.
Case Presentation: The patient presented here was positive for SARS-CoV-2, had severe acute respiratory distress
syndrome and multi-organ failure. Within days of admission to the intensive care unit he developed oliguric acute
kidney failure requiring dialysis. Acute kidney injury developed in the setting of hemodynamic instability, sepsis and
a maculopapular rash. Over the ensuing days the patient also developed transfusion-requiring severe hemolysis
which was Coombs negative. Schistocytes were present on the peripheral smear. Given the broad differential
diagnoses for acute kidney injury, a kidney biopsy was performed and revealed granulomatous tubulo-interstitial
nephritis with some acute tubular injury. Based on the biopsy findings, a decision was taken to adjust medications
and initiate corticosteroids for presumed medication-induced interstitial nephritis, hemolysis and maculo-papular
rash. The kidney function and hemolysis improved over the subsequent days and the patient was discharged to a
rehabilitation facility, no-longer required dialysis.
Conclusions: Acute kidney injury in patients with severe COVID-19 may have multiple causes. We present the first
case of granulomatous interstitial nephritis in a patient with COVID-19. Drug-reactions may be more frequent than
currently recognized in COVID-19 and are potentially reversible. The kidney biopsy findings in this case led to a
change in therapy, which was associated with subsequent patient improvement. Kidney biopsy may therefore have
significant value in pulling together a clinical diagnosis, and may impact outcome if a treatable cause is identified.
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Background
Acute kidney injury (AKI) associated with severe corona-
virus disease 19 (COVID-19) is common and is a significant
predictor of morbidity and mortality, especially when dialy-
sis is required [1–6]. Case reports and autopsy series have
revealed that most patients with COVID-19-associated AKI
have evidence of acute tubular injury (ATI) and/or acute
tubular necrosis (ATN) - not unexpected in critically ill
patients [7–9]. A mild associated interstitial infiltrate
may be present [10]. Other biopsy findings have in-
cluded collapsing glomerulopathy (associated with Afri-
can ancestry and a high-risk APOL1 genotype [11, 12],
thrombotic microangiopathy, and diverse underlying
kidney diseases [8, 13]. Kidney infarction has also been
reported [14]. A primary kidney pathology related to
COVID-19 has not yet emerged. Thus far direct infection
of the kidney remains controversial [8, 10, 13]. Recent
description of viral particles in the tubular epithelium may
support this possibility, although the clinical significance
of this remains unknown [15].
At present, the management of AKI is supportive.
During the first wave of SARS Cov2, around 1 in 4 pa-
tients with severe COVID and intubated the intensive
care unit (ICU) require dialysis [6, 16]. Mortality rates
are higher in patients with hospital-acquired AKI com-
pared with community-acquired AKI associated with
COVID-19 [4]. Ongoing vigilance is therefore required
throughout the hospital course. Many patients, given the
severity of illness, receive multiple medications including
a variety of antibiotics, and increasingly potential therapies
are being tested with encouraging results. Patients may
therefore be expected to be at risk of drug-associated
hypersensitivity [17, 18]. Initially the use of corticosteroids
was not routinely advocated, however recent data showed
a reduction in 28-day mortality when used in severe
COVID-19 [19]. How these therapies may impact AKI
and renal recovery in patients with COVID-19 remains
unknown. Here we report a patient with severe COVID-
19 who had developed AKI in the setting of multiorgan
dysfunction, a skin rash and hemolysis. After nephrology
consultation, a kidney biopsy was performed, which led to
a change in management and patient improvement.
Case presentation
A 62-year-old Caucasian man presented with symptoms
of cough, fever, myalgia and chills. Symptoms had begun
6 days prior to admission. He had tested positive for
SARS-CoV-2 by Xpert Xpress SaRS-CoV-2 (Cepheid,
Dx System Version 4.8) three days after symptom
onset. His past medical history was unremarkable
except for hyperlipidemia treated with atorvastatin
40 mg daily. No allergies were reported, the patient
did not smoke, drink alcohol or use illicit substances.
Kidney function was normal on admission.
Computed tomography (CT) scan of the chest, abdo-
men and pelvis excluded pulmonary emboli and showed
diffuse bilateral ground-glass infiltrates of the lungs with
associated lymphadenopathy, moderate pleural effusions,
normal-sized and -shaped kidneys with adequate perfu-
sion and without cortical defects.
Two days after admission the patient required intubation
due to acute respiratory distress syndrome (ARDS). He was
managed with prone positioning and was initiated on
hydroxychloroquine after exclusion of glucose-6-phosphate
dehydrogenase (G6PD) deficiency. Antibiotic therapy with
amoxicillin-clavulanate was given empirically assuming bac-
terial superinfection of viral pneumonia. His clinical condi-
tion worsened with the development of atrial fibrillation,
AKI, paralytic ileus, hemolytic anemia and a maculopapular
rash on the trunk and lower extremities.
The chronologic sequence of medications and clinical
events are highlighted in Fig. 1. Laboratory results are
shown in Table 1. Details of affected organ systems,
diagnostics and therapies are listed in Table 2.
A maculo-papular skin rash developed on day 7 after
admission. Severe AKI with oliguria (AKIN 3), consecutive
fluid overload and metabolic acidosis necessitated initiation
of continuous veno-venous hemodiafiltration (CVVHDF)
on day 9. Peak creatinine was 519 umol/L, urinalysis
showed minimal proteinuria and microscopic hematuria.
Proteinuria subsequently increased significantly and micro-
scopic hematuria persisted, urine leucocytes were persist-
ently within the normal range. (Table 1).
Several days after initiation of CVVHDF (on day 24)
the patient developed severe microangiopathic hemolytic
anemia, Coombs negative, which was transfusion
dependent. Serologic screening was negative for HIV,
hepatitis B and C virus infection; anti-nuclear antibodies,
anti-DNA antibodies, anti-neutrophil cytoplasmic anti-
bodies, anti-cardiolipin antibodies and complement levels
were normal. Eosinophils were initially not significantly
elevated. There was no evidence of urinary obstruction or
rhabdomyolysis. Echocardiogram showed preserved cardiac
function.
Differential diagnosis of the AKI included acute
tubular injury (ATI) due to hemodynamic instability;
sepsis-associated AKI; ATI with pigmented tubular
casts as a consequence of hemolysis; thrombotic
microangiopathy - given the ongoing severe hemolysis
with schistocytes on peripheral smear (despite lack of
overt thrombocytopenia); collapsing glomerulopathy -
given the large rise in proteinuria,; and acute intersti-
tial nephritis associated with antibiotics - given
concurrent skin rash, although peripheral eosinophilia
and leucocyturia were not marked. In the absence of
improvement of kidney function a transcutaneous
renal biopsy was performed while the patient was
proned in ICU, 32 days after admission.
Szajek et al. BMC Nephrology           (2021) 22:19 Page 2 of 8
Light microscopy revealed 34 mostly normal glomeruli.
Few glomeruli were mildly congested, without thrombi.
There was diffuse interstitial edema and focal infiltrates
with lymphocytes, histiocytes, rare plasma cells, neutro-
phils and eosinophils. Multiple non-caseating granulomas
mostly consisting of lymphocytes and epithelioid histio-
cytes (Fig. 2) were present. There was very mild tubulitis
with rare lymphocytes in the tubular epithelium. Many tu-
bules had a dilated lumen, flattened epithelium and loss of
brush border. Some had fine, isometric vacuolization of
the cytoplasm. Rare lumina contained finely granular,
mostly eosinophilic and very rare brownish casts only
partially positive for hemoglobin in a few tubules. Some
peritubular capillaries contained mononuclear cells, but
no erythrocyte aggregation. There was mild arteriolar hya-
linosis and arteriosclerosis, but no thrombi or vasculitis.
Immunhistochemistry showed only trace IgM, Kappa and
Lambda in the mesangium. IgG, IgA, C3 and C1q were
negative in the glomeruli. Electron microscopy revealed
myelin figures in the cytoplasm of a few parietal epithelia.
No definite viral particles were detected.
The biopsy was consistent with granulomatous tubuloin-
terstitial nephritis, acute tubular injury and regeneration.
There was no evidence of renal thrombotic microangiopa-
thy, collapsing glomerulopathy or vasculitis.
Mycobacterium tuberculosis infection as excluded and
confirmed by negative cultures of urine and tracheal se-
cretions. Serology for Sjogren’s Syndrome was negative.
Sarcoidosis was considered clinically unlikely, despite
thoracic lymphadenopathy which was interpreted as
consistent with severe SARS Cov2 pneumonia. The ion-
ized calcium levels were normal or low during the ICU
stay. Angiotensin converting enzyme and Interleukin-2
levels were however not measured. The biopsy findings
could not explain the proteinuria, which was interpreted
as a consequence of kidney injury and profound inflam-
mation associated with SARS Cov2 infection.
Given that a medication reaction was a potential cause
for kidney biopsy findings as well as for the rash and the
hemolysis, a multidisciplinary decision was taken to stop
ß-lactams, amiodarone and pantoprazole and to begin
methylprednisolone 60 mg daily on day 37 (Fig. 1). 47
days after admission urine output began to improve and
CVVHDF was discontinued. The hemolysis resolved, the
skin rash improved.
On transfer to neurorehabilitation 48 days after admis-
sion, the patient was tetraparetic due to critical illness
polyneuropathy but alert and able to follow simple com-
mands, he had tracheostomy in place and was breathing
spontaneously with little support. The course of rehabilita-
tion showed progressive improvement of kidney function
(Fig. 1). The estimated GFR two months post-discharge
was 43 ml/min/1,73 m2 suggesting a likely transition to
chronic kidney disease.
Discussion and conclusions
The underlying pathophysiology of impaired kidney
function in patients suffering from COVID-19 is likely
Fig. 1 Timeline
Szajek et al. BMC Nephrology           (2021) 22:19 Page 3 of 8
complex and multifactorial and to date incompletely
understood [8, 13, 20]. Virus-induced sepsis with
hemodynamic instability and renal hypoperfusion may
promote ATI [9, 21, 22]. Upregulation of proinflamma-
tory cytokines and chemokines in the setting of sepsis,
generally described as “cytokine storm”, may trigger
multiorgan failure including ATI [20, 23, 24]; SARS-
CoV-2-associated hypercoagulability may aggravate
endothelial dysfunction leading to microangiopathy and
collapsing glomerulopathy [25–27]. SARS-CoV-2 RNA
has been isolated in urine and viral particles have been
demonstrated in post-mortem kidney tissue by some au-
thors but not others [9, 10, 15] suggesting possible renal
tropism of the virus, although others have failed to find
viral RNA in kidney tissue by in-situ hybridization or
RT-PCR in kidney biopsies [28, 13]. Internalisation of
coronavirus into kidney tissue may potentially be medi-
ated through the angiotensin-converting enzyme 2
(ACE2) receptor [9, 20, 29].
We report a case of GIN in a patient with COVID-19
who required prolonged CVVHDF. Clinical evidence of
thrombotic microangiopathy on the background of oli-
guric AKI, proteinuria and hematuria had prompted the
kidney biopsy. Surprisingly no evidence of thrombotic
microangiopathy or significant pigmented tubular casts
was found. Interestingly, the patient had no evidence of






















Urea, mmol/l 2.76–8.07 - 37.4 CVVHD CVVHD CVVHD 29.8
Creatinine, umol/l 59–104 87 498 CVVHD CVVHD CVVHD 130
Albumin, g/l 39.7–49.5 - 18.5 19.1 25.8 19.8 22.7
CRP, mg/l < 5 223 310 339 150 201 27.1
PCT, ng/ml < 0.5 0.29 2.42 9.13 3.71 5.05 2.56
Ferritin, ug/l 30–400 - > 11,063 - 2505 4646 3480
D-dimer, mg/l < 0.5 1.38 3.98 2.55 2.77 2.63 -
IL-6, pg/ml < 7 - - - - 56.2 -
AST, U/l < 40 60 252 49 68 73 38
ALT, U/l < 50 78 146 43 35 47 78
Bilirubin totally, umol/l 3.4–17 - 15.1 29.4 17.3 24 -
Bilirubin indirect, umol/l < 12.8 - 0.9 3.9 - - -
Hemoglobin, g/l 140–180 138 91 69 72 78 71
Schistocytes - + +
Platelet count 139–335 10E3/ul 241 612 598 501 298 513
Haptoglobin, g/l 0.3-2.0 - - < 0.1 < 0.1 < 0.1 0.91
LDH, U/l 240–480 770 999 1173 1125 1109 636
Coombs test Positive/negative - - - negative - -
WBC count 3.5–10 10E3/ml 10 8.6 36.5 25.8 23.8 12.9
Eosinophils 0.08–0.36 10E3/ul 0.01 0.11 0.51 0.12 1.10 0.68
URINE ANALYSIS
Fractional excretion of Urea (%) - 46.8 - - - -
Urine PCR, mg/mmol < 20 - 72.6 - - - -
Urine ACR,
mg/mmol
< 3 - 5.3 - - - -
Urine,
red blood cells, /ul
< 23 10 388 - 13.6 829 3
(03.05.)
Urine, leucocytes, /ul < 25 15 8 - 5.1 29.1 1
(03.05)
Abbreviations: CRP C-reactive proteine, PCT procalcitonin, IL-6 interleukin 6, AST aspartate amino transferase, ALT alanine aminotransferase, LDH lactate
dehydrogenase, WBC white blood cells, PCR protein/creatinine ratio, ACR albumine/creatinine ratio
a+/- 3 days
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leukocyturia and no significant eosinophilia prior to
biopsy, however significant eosinophilia was observed on
the day of biopsy (Table 1). The patient had no prior his-
tory of medication allergies or skin rashes, but histopatho-
logic findings of skin biopsy were in concordance with an
allergic, drug-induced skin reaction (Table 2). Consistent
with the possibility of a drug-induced etiology, AKI devel-
oped at the same time as the skin rash. The rash had been
presumed to be related to Amoxicillin, which had been
discontinued. However our patient subsequently received
various other beta-lactam antibiotics as illustrated in Fig. 1.
Skin rashes are common in patients with COVID-19, with
maculo-papular rashes being the most frequent[30]. A
drug-induced etiology is often hypothesized as these
patients tend to be sicker and thus receive multiple medi-
cations compared with patients with other rashes.
The patient described here also developed severe
coombs-negative hemolytic anemia with schistocytes on
peripheral blood smear. Criteria for thrombocytopenia were
not met, but platelet counts did drop by approximately
60%. Work-up excluded thrombotic thrombocytopenic
purpura (normal serum-ADAMTS19 activity), paroxysmal
nocturnal hematuria or glucose-6-phosphate-deficiency.
There was no evidence of hereditary erythrocyte membrane
disorder or hemoglobinopathy. An association between
hemolytic anemia and interstitial nephritis has been de-
scribed [31], although in general these cases had a positive
Coombs test indicating immune-mediated hemolysis
induced by medication. Drug-induced immune-mediated
hemolysis with a negative Coombs test, potentially falsely
negative due to the severity of the hemolysis and number
of transfusions, has however been reported [32]. We were
Table 2 Affected organ systems and therapeutic measures
Affected organ system /
Medical problem
Diagnostics / Results Therapy
Severe acute respiratory distress
syndrome (ARDS) with PaO2/FiO2
ratio as deep as 80
CT scan thorax / bilateral ground-glass





- ventilator associated pneumonia with
Proteus vulgaris and sepsis
- viral pneumonia with Herpes simplex
virus 1




Acute kidney injury (AKI) Kidney biopsy / granulomatous
tubulointerstitial nephritis
Continous veno-venous hemodiafiltration
Discontinuation of beta-lactams & proton
pump inhibitor
Corticosteroid therapy
Encephalopathy - CT and MRI head / multiple intracranial
microhemorrhages
- EEG/ no epileptic activity
Termination of unnecessary medication
Temporary reduction of anticoagulation
Physiotherapy
Hemodynamic instability ECG / Intermittent atrial fibrillation
Echocardiography / left ventricular









evidence of paroxysmal nocturnal
hemoglobinuria
Transfusion of packed red blood cells
Discontinuation of imipenem and
amiodarone
Corticosteroid therapy
Local bleeding after tracheostomy
without hemodynamic instability
Clinical examination Transfusion of packed red blood cells
Mechanical compression
Critical illness polyneuropathy Diffuse, symmetric, flaccid paresis,
muscle weakness
Physiotherapy, discharge to rehabilitation
facility
Hepatopathy Hepatitis B and C negative
No cholestasis on imaging
Reduction of hepatotoxic medication
Maculopapular rash Skin biopsy / dermoepidermal junction
with focal vacuolization; lymphocytic
infiltrates and rare eosinophils within the
corium, discrete vasculitic changes and
extravasates of erythrocytes; consistent
with drug-induced exanthema; negative
for SARS-CoV-2
Corticosteroids topically and systemically
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unable to measure specific anti-antibiotic antibodies to test
this hypothesis and cannot exclude drug-induced
hemolysis. In recent months several cases of auto-immune
hemolytic anemias (Coombs positive) in patients with
COVID-19 have been described, but most appear to have
been associated with underlying diseases and severe AKI
was not reported. Of note direct association with COVID
itself was postulated in 2 cases [33–35]. Importantly, most
of these patients responded favorably to steroid therapy, as
did the patient reported here. The presence of schistocytes
in the peripheral blood smear in our patient suggests the
presence of a microangiopathy, which we were not able to
detect in the kidney biopsy. As SARS-CoV-2 infection may
be associated with endothelial injury [20, 25], however,
the hemolysis may have reflected microvascular injury
elsewhere.
GIN is rarely observed in kidney biopsies (< 1% of
native kidney biopsies), and the differential diagnosis is
broad and challenging [36]. Apart from the usual suspects
including medications (especially antibiotics and nonsteroi-
dal anti-inflammatory drugs) and autoimmune disorders
(i.e. vasculitis, especially granulomatosis with polyangiitis,
sarcoidosis, tubulointerstitial nephritis with uveitis (TINU)-
syndrome), microorganisms such as mycobacteria and
fungi have been implicated [37]. We could not find evi-
dence of these diseases in the current case. In the case
presented here, tuberculosis was excluded with negative
cultures and autoimmune disorders were excluded with
negative serologies. Sarcoidosis could not be completely
ruled out, but given the lack of sharply defined granulomas
in the biopsy and in the absence of Schaumann bodies, the
histology was most consistent with a drug-induced cause
for the GIN. A follow-up serum calcium after hospital
discharge, when the patient was no longer on steroids
remained within the normal range. Myelin bodies described
in the biopsy were sparse, not consistent with a diagnosis of
Fabry’s Disease, and were more likely associated with
hydroxychloroquine or amiodarone use. Both medications
were discontinued. A further differential diagnosis of GIN
in our patient included secondary hemophagocytic lympho-
histiocytosis (sHLH), which has been associated with
COVID-19 [38]. Also known as macrophage activation syn-
drome, it is a systemic inflammatory syndrome, manifest by
a fulminant hypercytokinemia [20, 39, 40]. The clinical pic-
ture is broad including fever, hepatosplenomegaly, hepato-
biliary dysfunction and pulmonary involvement (including
ARDS). Renal injury and cutaneous rash – as present in
our patient – may also occur [39]. Laboratory abnormalities
include cytopenias, coagulopathy, altered liver function test,
hypertriglyceridemia and hyperferritinemia [39]. A bone
marrow aspirate was not performed, but given the multior-
gan dysfunction and the very high ferritin levels sHLH
could not be entirely excluded. Drug reaction with eosino-
philia and systemic symptoms (DRESS) syndrome associ-
ated with hydroxychloroquine or azithromycin has been
reported in a patient with COVID-19 [41]. This patient had
mild renal dysfunction and responded to corticosteroid
therapy. DRESS syndrome was unlikely in our patient how-
ever, given the absence of significant eosinophilia and only
transient elevation in liver enzymes.
Taken together, a medication-related etiology of GIN
leading to AKI, and possibly to hemolysis and the skin
rash, seems most likely here. Whether and how the
background inflammatory milieu of COVID-19 might
Fig. 2 a: Kidney biopsy with interstitial infiltrates of mostly lymphocytes, histiocytes and plasma cells and a noncaseating granuloma (arrowheads)
(PAS, Periodic acid-Schiff reaction). b: Detail of another peritubular granuloma with lymphocytes and epithelioid macrophages (arrows) (PAS)
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have modulated the disease phenotype or independently
contributed to the findings remains unclear. The rapidity
of the clinical response in terms of improvement of
kidney function and hemolysis suggests a benefit from
corticosteroid therapy in this patient. At the time of
treatment, corticosteroid therapy was not routinely
recommended in COVID-19, and there was even some
hesitation about their use. The kidney biopsy findings
however prompted in-depth multi-disciplinary discus-
sion and re-review of all the clinical findings and led to
a decision to initiate corticosteroid therapy.
Interstitial infiltrates have not commonly been
described in the published kidney biopsy series from
patients with COVID-19 [8, 10, 13]. As most patients
with severe COVID-19 in the ICU likely receive multiple
medications known to be associated with interstitial
nephritis, this finding may be somewhat surprising.
Discussion of the risk of drug reactions in the literature
has thus far focused on potential specific therapeutic
agents for COVID-19 itself [17, 18], although many
other medications are used simultaneously given the
severity of illness (Fig. 1). The risk of medication-
associated adverse reactions may therefore be more clinic-
ally relevant than recognized. Based on the findings in this
case, we suggest that this diagnosis should be considered
more frequently as a potential indication for a kidney bi-
opsy as there may be important therapeutic consequences.
Given the clinically unexpected finding of GIN in this
case and the favorable response to treatment, we suggest
that nephrology consultation and kidney biopsy are of
value in better understanding the pathophysiology of
renal involvement in patients suffering from SARS-CoV2
infection. Even late in the course a kidney biopsy may
lead to changes in therapy which can positively impact
outcomes.
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